Currently, standard tests like prostate specific antigen (PSA) for diagnosing and tracking prostate cancer progress are inadequate in determining the frequency of different cancer phenotypes, including drug-resistant ones. This evidence concerns the gene KLK3 and Familial prostate cancer.